Literature DB >> 31342730

Identifying Smoking-Related Disease on Lung Cancer Screening CT Scans: Increasing the Value.

Elizabeth A Regan1,2, Katherine E Lowe1,2, Barry J Make1, David A Lynch1, Gregory L Kinney2, Matthew J Budoff3, Song Shou Mao3, Debra Dyer1, Jeffrey L Curtis4,5, Russell P Bowler1, MeiLan K Han4, Terri H Beaty6, John E Hokanson2, Elizabeth Kern1, Stephen Humphries1, Douglas Curran-Everett1, Edwin J R van Beek7, Edwin K Silverman8, James D Crapo1, James H Finigan1.   

Abstract

BACKGROUND: Lung cancer screening (LCS) via chest computed tomography (CT) scans can save lives by identifying early-stage tumors. However, most smokers die of comorbid smoking-related diseases. LCS scans contain information about smoking-related conditions that is not currently systematically assessed. Identifying these common comorbid diseases on CT could increase the value of screening with minimal impact on LCS programs. We determined the prevalence of 3 comorbid diseases from LCS eligible scans and quantified related adverse outcomes.
METHODS: We studied COPD Genetic Epidemiology study (COPDGene®) participants (n=4078) who met criteria for LCS screening at enrollment (age > 55 years, and < 80 years, > 30 pack years smoking, current smoker or former smoker within 15 years of smoking cessation). CT scans were assessed for coronary artery calcification (CAC), emphysema, and vertebral bone density. We tracked the following clinically significant events: myocardial infarctions (MIs), strokes, pneumonia, respiratory exacerbations, and hip and vertebral fractures.
RESULTS: Overall, 77% of eligible CT scans had one or more of these diagnoses identified. CAC (> 100 mg) was identified in 51% of scans, emphysema in 44%, and osteoporosis in 54%. Adverse events related to the underlying smoking-related diseases were common, with 50% of participants reporting at least one. New diagnoses of cardiovascular disease, emphysema and osteoporosis were made in 25%, 7% and 46%, of participants respectively. New diagnosis of disease was associated with significantly more adverse events than in participants who did not have CT diagnoses for both osteoporosis and cardiovascular risk.
CONCLUSIONS: Expanded analysis of LCS CT scans identified individuals with evidence of previously undiagnosed cardiovascular disease, emphysema or osteoporosis that corresponded with adverse events. LCS CT scans can potentially facilitate diagnoses of these smoking-related diseases and provide an opportunity for treatment or prevention. JCOPDF
© 2019.

Entities:  

Keywords:  chronic obstructive pulmonary disease; comorbidities; copd; lung cancer screenings; smoking-related disease

Year:  2019        PMID: 31342730      PMCID: PMC6872218          DOI: 10.15326/jcopdf.6.3.2018.0142

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  52 in total

1.  Relationships between airflow obstruction and quantitative CT measurements of emphysema, air trapping, and airways in subjects with and without chronic obstructive pulmonary disease.

Authors:  Joyce D Schroeder; Alexander S McKenzie; Jordan A Zach; Carla G Wilson; Douglas Curran-Everett; Douglas S Stinson; John D Newell; David A Lynch
Journal:  AJR Am J Roentgenol       Date:  2013-09       Impact factor: 3.959

2.  Association of Coronary Artery Calcification and Mortality in the National Lung Screening Trial: A Comparison of Three Scoring Methods.

Authors:  Caroline Chiles; Fenghai Duan; Gregory W Gladish; James G Ravenel; Scott G Baginski; Bradley S Snyder; Sarah DeMello; Stephanie S Desjardins; Reginald F Munden
Journal:  Radiology       Date:  2015-03-09       Impact factor: 11.105

3.  Defining the path: lung cancer CT screening in Europe.

Authors:  Matthew E Callister; Sam M Janes
Journal:  Thorax       Date:  2017-07-19       Impact factor: 9.139

4.  Improving hip fractures outcomes for COPD patients.

Authors:  Elizabeth A Regan; Tiffany A Radcliff; William G Henderson; Diane C Cowper Ripley; Matthew L Maciejewski; W Bruce Vogel; Evelyn Hutt
Journal:  COPD       Date:  2012-12-28       Impact factor: 2.409

5.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

6.  Results of initial low-dose computed tomographic screening for lung cancer.

Authors:  Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum
Journal:  N Engl J Med       Date:  2013-05-23       Impact factor: 91.245

7.  Visual Assessment of CT Findings in Smokers With Nonobstructed Spirometric Abnormalities in The COPDGene® Study.

Authors:  Song Soo Kim; Kunihiro Yagihashi; Douglas S Stinson; Jordan A Zach; Alexander S McKenzie; Douglas Curran-Everett; Emily S Wan; Edwin K Silverman; James D Crapo; David A Lynch
Journal:  Chronic Obstr Pulm Dis       Date:  2014

8.  CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes.

Authors:  Elisabeth A P M Romme; John T Murchison; Lisa D Edwards; Edwin van Beek; David M Murchison; Erica P A Rutten; Frank W J M Smeenk; Michelle C Williams; Emiel F M Wouters; William MacNee
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

9.  Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement.

Authors:  Albert L Siu; Kirsten Bibbins-Domingo; David C Grossman; Karina W Davidson; John W Epling; Francisco A R García; Matthew Gillman; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Diane M Harper; William R Phillips; Maureen G Phipps; Michael P Pignone
Journal:  JAMA       Date:  2016-04-05       Impact factor: 56.272

10.  Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality.

Authors:  Michelle C Williams; John T Murchison; Lisa D Edwards; Alvar Agustí; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; Bruce E Miller; Steve Rennard; Edwin K Silverman; Ruth Tal-Singer; Jørgen Vestbo; Emiel Wouters; Julie C Yates; Edwin J R van Beek; David E Newby; William MacNee
Journal:  Thorax       Date:  2014-01-28       Impact factor: 9.139

View more
  5 in total

1.  Functional imaging of COPD by CT and MRI.

Authors:  David A Lynch
Journal:  Br J Radiol       Date:  2021-09-19       Impact factor: 3.629

2.  Comparison of CT Lung Density Measurements between Standard Full-Dose and Reduced-Dose Protocols.

Authors:  Charles R Hatt; Andrea S Oh; Nancy A Obuchowski; Jean-Paul Charbonnier; David A Lynch; Stephen M Humphries
Journal:  Radiol Cardiothorac Imaging       Date:  2021-04-22

3.  Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Charles R Hatt; Abdullah Al-Abcha; Michael C Ferrera; Catherine A Meldrum; Lauren A Keith; Craig J Galbán; Douglas A Arenberg; Jeffrey L Curtis; Fernando J Martinez; Ella A Kazerooni; MeiLan K Han
Journal:  Chest       Date:  2020-12-14       Impact factor: 9.410

4.  Prevalence, symptom burden and under-diagnosis of chronic obstructive pulmonary disease in Polish lung cancer screening population: a cohort observational study.

Authors:  Aleksandra Undrunas; Piotr Kasprzyk; Aleksandra Rajca; Krzysztof Kuziemski; Witold Rzyman; Tomasz Zdrojewski
Journal:  BMJ Open       Date:  2022-04-11       Impact factor: 2.692

5.  Computed tomography on lung cancer screening is useful for adjuvant comorbidity diagnosis in developing countries.

Authors:  Juliane Nascimento de Mattos; Carlos Eugênio Santiago Escovar; Manuela Zereu; Adalberto Sperb Rubin; Spencer Marcantonio Camargo; Tan-Lucien Mohammed; Ricardo Sales Dos Santos; Nupur Verma; Diana Penha Pereira; Erique Guedes Pinto; Tiago Machuca; Tássia Machado Medeiros; Bruno Hochhegger
Journal:  ERJ Open Res       Date:  2022-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.